The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

FDA approves subcutaneous Opdivo, enhancing cancer treatment with similar efficacy to intravenous form and improved patient ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...

The FDA approves an injectable Opdivo cancer drug; Axsome seeks approval for an Alzheimer's drug amid mixed results; Hain ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...